Related Experiment Video
Updated: Aug 11, 2025

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
The New Congress and Pharmacy Benefit Manager Reform: Will the Insurers Escape Again?
1Baldwin Health Policy Group LLC.
Abstract:
The Pharmacy Benefit Management industry is one which seems to attract bipartisan scorn, similar to the pharmaceutical manufacturers. Despite widespread criticism for many years, the manufacturers were finally presented with a big setback with the passage of the Inflation Reduction Act, which included a provision to require price negotiation in Medicare for prescription drugs. The provision does not go into effect until 2026, giving manufacturers time to escape-if they are able.
More Related Videos
08:31Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
Published on: December 1, 2020
09:40Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes
Published on: September 28, 2018
Related Concept Videos
Drug Control Governance: Regulatory Bodies and Their Impact
Drug Regulation
Biopharmaceutics and Pharmacokinetics: Overview
Issues And Trends In Healthcare Delivery System
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...
Standards of Care II
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...